Das Gesundheitswesen
-
Das Gesundheitswesen · Jun 2020
Review[Quarantine Alone or in Combination with Other Public Health Measures to Control COVID-19: A Rapid Review (Review)].
COVID-19 (coronavirus disease 2019) is a new, rapidly emerging zoonotic infectious disease, that was reported to the World Health Organization for the first time on 31 December 2019. Currently, no effective pharmacological interventions or vaccines are available to treat or prevent COVID-19, therefore nonpharmacological public health measures are more in focus. ⋯ Our confidence in the evidence is very limited. This is mainly because the COVID-19 studies based their models on the limited data that have been available in the early weeks of the pandemic and made different assumptions about the virus. The studies of SARS and MERS are not completely generalizable to COVID-19. Despite only having limited evidence, all the studies found quarantine to be important for controlling the spread of severe coronavirus diseases. Looking to the coming months, in order to maintain the best possible balance of measures, decision makers must continue to constantly monitor the outbreak situation and the impact of the measures they implement.
-
Das Gesundheitswesen · Mar 2020
Comparative Study[Survey of Relatives' Perspective on Dying In The Hospital: A Comparison Between Departments of Internal Medicine and Palliative Care In Styria (Austria)].
Currently, 49% of deaths in Austria occur in a hospital which makes in-patient quality of care as well as quality of death and dying a highly relevant topic. In this article, we compare the quality of care and death and dying in departments of internal medicine and palliative care in hospitals from the perspective of relatives. ⋯ Against the background of the large proportion of individuals who die in hospitals in Austria, this exploratory study showed that relatives perceived both better quality of care and better quality of death and dying in the assessed departments of palliative care compared to the departments of internal medicine. Thus, a more comprehensive and systematic evaluation of the potential added value of palliative care teams in Austrian hospitals is recommended.
-
Das Gesundheitswesen · Jul 2019
["It Is Up To You": A Qualitative Study of Inequalities In Healthcare From The Patient's Perspective].
The aim of this qualitative study was to explore inequalities in healthcare from the patient's perspective. ⋯ From the patient´s point of view, their own capacity to orient and engage themselves in the healthcare system, as well as reduction of barriers to accessing outpatient care are highly important for reducing inequalities in healthcare.
-
Das Gesundheitswesen · May 2019
[Substance Abuse Poisoning Reported to the Poisons Information Centre Erfurt from 2002 to 2016].
Poisoning due to substance abuse has changed significantly during the last few years. Therefore, developments of substance abuse reported to the Poisons Information Centre Erfurt were investigated and compared to other circumstances of human exposures during the last 15 years. ⋯ Clinical significance of substance abuse is shown by the fact that it resulted more often in moderate and severe symptoms than suicide attempts. Data of substance abuse from PICs could supplement those on clinical toxicology in official annual drug reports.
-
Das Gesundheitswesen · Jun 2018
[Benefit Assessment and Price Negotiation Under AMNOG: Calculable Process or Unfair Poker Game?]
Ever since the introduction of the Market Restructuring Act, the evaluation and price negotiations of drugs have been controversial. While the Federal Joint Committee considers that the process is transparent and in accordance with clear evidence-based criteria, representatives of pharmaceutical companies are particularly critical of the fact that the central association of statutory health insurance is involved in both the determination of added therapeutic benefit of drugs as well as in the subsequent price negotiation. In this study, we investigate these 2 contradictory assessments empirically. ⋯ We show that the number of patients in the target population, and the annual cost of therapy for the appropriate comparator therapy have a negative influence on the determination of the added benefit of the new therapy. The added value itself has a positive (negative) effect on the mark-up for the appropriate comparator therapy (price discount), while the annual treatment costs of the new therapy (which appropriate comparator therapy) have a positive (negative) influence. We find clues, but no significant evidence for the hypothesis that the decisions on the added value of new medicines and the subsequent price negotiations are interdependent.